• SPX
  • $5,712.69
  • -0.28 %
  • -$16.11
  • DJI
  • $41,794.60
  • -0.61 %
  • -$257.59
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,203.29
  • 0.23 %
  • $19.05
  • IXIC
  • $18,179.98
  • -0.33 %
  • -$59.93
Karuna Therapeutics, Inc. (KRTX) Stock Price, News & Analysis

Karuna Therapeutics, Inc. (KRTX) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$329.75
Day's range
$329.97
50-day range
$296.06
Day's range
$329.99
  • Country: US
  • ISIN: US48576A1007
52 wk range
$158.38
Day's range
$329.99
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 91.07
  • Piotroski Score 1.00
  • Grade Neutral
  • Symbol (KRTX)
  • Company Karuna Therapeutics, Inc.
  • Price $329.83
  • Changes Percentage (0.03%)
  • Change $0.09
  • Day Low $329.75
  • Day High $329.97
  • Year High $329.99

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 05/01/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $272.50
  • High Stock Price Target $330.00
  • Low Stock Price Target $150.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$11.74
  • Trailing P/E Ratio -28.094548551959
  • Forward P/E Ratio -28.094548551959
  • P/E Growth -28.094548551959
  • Net Income $-433,680,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.